Eczema and Glaucoma in Young Adults: A 1.73 Hazard Ratio Was Not a 73% Chance of Disease

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar in an original canoe-club scene; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

A glaucoma risk headline can sound much more alarming than the underlying numbers. A 2024 Korean study found an association with atopic dermatitis, but its hazard ratio does not tell an individual that glaucoma is likely—or that eczema caused an eye condition.

The eczema subgroup was much smaller than the full cohort

The primary nationwide cohort paper analyzed 171,129 people aged 20–39 at baseline using health-screening and medical-claims information. Only 810 had the study’s atopic dermatitis classification. The comparison without AD contained 170,319 people. The sample should not be described as 171,129 eczema patients.

Atopic dermatitis classification	People	Glaucoma events	Rate per 1,000 person-years
AD	810	58	9.35
No AD	170,319	6,763	4.83

The fully adjusted hazard ratio for AD was 1.73, with a 95% confidence interval of 1.34–2.24. Adjustment included demographic and health factors as well as a history of steroid use. These figures refer to primary open-angle glaucoma detected during follow-up.

Rates and hazards answer different questions

Person-years combine participants’ observed follow-up time. A rate of 9.35 per 1,000 person-years is not a statement that 9.35% of people developed glaucoma each year. The hazard ratio compares the modeled rate of occurrence over time, after the listed adjustments; it is not a 73% absolute probability.

The crude rates and adjusted hazard ratio also should not be treated as interchangeable. Their differences reflect how the analyses account for measured factors. Neither calculation can provide a personalized forecast without considering a person’s age, family history, eye findings and other relevant information.

An association cannot assign a cause

Claims-based diagnoses can be misclassified. The authors could not fully assess eczema severity or subtype and acknowledged possible detection bias: people attending health services more often may be more likely to receive a glaucoma diagnosis. Statistical adjustment cannot remove every unmeasured difference.

The steroid-use variable grouped different exposures; adjustment for it does not prove steroids caused the association or prove that a particular medicine could not affect an individual’s eye pressure. Do not stop prescribed skin or eye treatment on the basis of this cohort.

What to discuss about eye checks

The National Eye Institute explains that glaucoma often has no early symptoms and requires an eye examination to detect. Ask an eye professional how your own risk factors affect the timing of checks. This observational study did not test whether one screening schedule improves outcomes for everyone with eczema.

For adults balancing work, exercise and appointments, bring an accurate list of current and past medicines, including eye drops, inhalers and skin treatments. Describe any visual changes rather than assuming they are simply irritation from sweat or dry eyelids.

Sudden intense eye pain with a red eye, blurred vision or nausea needs urgent assessment; NEI distinguishes those warning symptoms from the often silent onset of open-angle disease. Our related eye-symptom guide addresses a separate question about symptoms during dupilumab use.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.